T Regulatory Cells in Donor Grafts May Predict the Severity of Acute Graft Versus Host Disease After Matched Sibling Donor Allogenic Peripheral Blood Stem Cell Transplantation.
Acute GVHD
Allo-HSCT
T-regulatory cells
Journal
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
ISSN: 0971-4502
Titre abrégé: Indian J Hematol Blood Transfus
Pays: India
ID NLM: 9425818
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
05
10
2018
accepted:
26
12
2018
entrez:
17
4
2019
pubmed:
17
4
2019
medline:
17
4
2019
Statut:
ppublish
Résumé
Acute graft-versus-host disease (aGVHD) and relapse are major issues for patients undergoing allogenic hematopoietic stem cell transplant (allo-HSCT). T-regulatory (Treg) cells in the donor graft are negatively correlated with the incidence of aGVHD without any impact on relapse. In this study to determine the association of Treg cells with aGVHD in allo-HSCT patients. Thirty-two patients with hematological disorders, who underwent allo-HSCT. Twenty-nine patients who achieved engraftment were enrolled in the study. Treg cells were quantified in donor graft by flowcytometry and were assessed for their association with aGVHD and other clinical outcomes. Fifteen of 29 patients developed aGVHD. According to the occurrence and severity of aGVHD, patients were divided into two groups: 20 (68.9%) patients with grade 0-I aGVHD and 9 (31.1%) patients with grade II-IV aGVHD. Treg cells/CD4 ratio was significantly higher in the grade 0-I aGVHD group than in grade II-IV aGVHD group, (
Identifiants
pubmed: 30988557
doi: 10.1007/s12288-018-01071-9
pii: 1071
pmc: PMC6439099
doi:
Types de publication
Journal Article
Langues
eng
Pagination
233-239Déclaration de conflit d'intérêts
Authors have no conflict of interest to declare.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.Informed consent was obtained from all individual participants included in the study.
Références
J Immunol. 1999 May 1;162(9):5317-26
pubmed: 10228007
Blood. 1999 Aug 15;94(4):1465-70
pubmed: 10438735
Blood. 2000 Jun 15;95(12):3702-9
pubmed: 10845900
Blood. 2001 Dec 1;98(12):3221-7
pubmed: 11719357
Blood. 2002 May 15;99(10):3493-9
pubmed: 11986199
Blood. 2002 Jul 15;100(2):724-7
pubmed: 12091376
Biol Blood Marrow Transplant. 2002;8(10):525-35
pubmed: 12434947
Blood. 2004 Feb 1;103(3):1140-6
pubmed: 12907445
Nat Med. 2003 Sep;9(9):1144-50
pubmed: 12925844
Blood. 2006 Aug 15;108(4):1291-7
pubmed: 16627754
J Exp Med. 2006 Jul 10;203(7):1701-11
pubmed: 16818678
J Immunol. 2006 Jul 15;177(2):840-51
pubmed: 16818738
Nat Rev Immunol. 2007 May;7(5):340-52
pubmed: 17438575
Transplantation. 2007 Apr 27;83(8):1107-13
pubmed: 17452902
Clin Cancer Res. 2007 May 15;13(10):2916-22
pubmed: 17504991
Biol Blood Marrow Transplant. 2007 Aug;13(8):965-74
pubmed: 17640601
Bone Marrow Transplant. 2012 Jan;47(1):107-14
pubmed: 21317935
Blood. 2012 Jan 5;119(1):296-307
pubmed: 22010102
Bone Marrow Transplant. 2016 Jan;51(1):110-8
pubmed: 26389831
Oncotarget. 2016 May 10;7(19):27255-66
pubmed: 27036034
Immunology. 1971 Dec;21(6):903-14
pubmed: 4943147
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
J Immunol. 1995 Aug 1;155(3):1151-64
pubmed: 7636184
J Exp Med. 1996 Aug 1;184(2):387-96
pubmed: 8760792